DESIGN AND DEVELOPMENT OF NANOBIOCOMPOSITE OF ANTI-INFLAMMATORY DRUG

To enhance the physicochemical properties of Soluplus® nanocomposites loaded with naproxen, this study's goal was to create and characterise them. In vitro percentage dissolving efficiency, nanocomposites' anti-inflammatory effectiveness, and the impact of polymer and surfactant concentration on particle size were also studied. Utilising the freeze- drying method, the nanocomposites were created. By using differential scanning calorimetry (DSC), Fourier transformation infrared spectroscopy (FTIR), X-ray powder diffractometry (XPRD), and scanning electron microscopy (SEM), the analytical evidence supporting the synthesis of lyophilized nanocomposites in the solid state was generated and confirmed. Comparing nanocomposites' in vitro drug release profile to that of Naproxen powder purified. The particle size and zeta potential of the naproxen nanocomposites were 64.6 nm and 47.6 mv, respectively, and they were all contained in the nano range. When compared to Naproxen alone, the nanocomposites' solubility and dissolution were significantly (p˂0.001) improved, as shown by their lowered log P values (1.90 ± 0.002). The results of the characterisation studies demonstrated that naproxen formed amorphous nanocomposites with the presence of physical contacts between the drug and polymer. The carrageenan-induced rat paw edoema model used to test the anti-inflammatory activity of nanocomposites revealed a non- significant (p>0.05) increase in anti-inflammatory activity when compared to pure naproxen. Based on the findings, it can be inferred that using Soluplus® to create Naproxen nanocomposites could be a useful and different strategy for changing the physicochemical characteristics of Naproxen.